Last update 21 Nov 2024

GEM3-PSCA

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
Target
CD3 x PSCA
Mechanism
CD3 stimulants(T cell surface glycoprotein CD3 stimulants), PSCA inhibitors(Prostate stem cell antigen inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]
Active Indication-
Inactive Indication
Breast CancerKidney NeoplasmsNon-Small Cell Lung Cancer+ [4]
Originator Organization
GEMoaB Monoclonals GmbHGEMoaB Monoclonals GmbH
Active Organization-
Inactive Organization
AvenCell Europe GmbHAvenCell Europe GmbHStartupAvenCell Therapeutics, Inc.GEMoaB Monoclonals GmbHGEMoaB Monoclonals GmbH
+ [1]
Drug Highest PhaseDiscontinuedPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with GEM3-PSCA
NCT03927573 / TerminatedPhase 1
A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM3PSCA, a PSCA Targeted Bispecific Antibody Engaging T-cells, in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSCA Marker
100 Clinical Results associated with GEM3-PSCA
Login to view more data
100 Translational Medicine associated with GEM3-PSCA
Login to view more data
100 Patents (Medical) associated with GEM3-PSCA
Login to view more data
100 Deals associated with GEM3-PSCA
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Kidney NeoplasmsPhase 1
DE
AvenCell Therapeutics, Inc.
15 Apr 2019
Kidney NeoplasmsPhase 1
DE
AvenCell Therapeutics, Inc.
15 Apr 2019
Kidney NeoplasmsPhase 1
DE
GCP Service International Ltd & Co KG
15 Apr 2019
Kidney NeoplasmsPhase 1
DE
AvenCell Europe GmbHAvenCell Europe GmbHStartup
15 Apr 2019
Kidney NeoplasmsPhase 1
DE
AvenCell Europe GmbHAvenCell Europe GmbHStartup
15 Apr 2019
Kidney NeoplasmsPhase 1
DE
GCP Service International Ltd & Co KG
15 Apr 2019
Pancreatic CancerPhase 1
DE
GEMoaB Monoclonals GmbHGEMoaB Monoclonals GmbH
15 Apr 2019
Prostatic CancerPhase 1
DE
AvenCell Therapeutics, Inc.
15 Apr 2019
Prostatic CancerPhase 1
DE
AvenCell Europe GmbHAvenCell Europe GmbHStartup
15 Apr 2019
Prostatic CancerPhase 1
DE
AvenCell Europe GmbHAvenCell Europe GmbHStartup
15 Apr 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free